Organization
Stanford University Medical Center
10 abstracts
Abstract
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Washington University in Saint Louis, University of Colorado Cancer Center, University of Pennsylvania-Abramson Cancer Center,
Abstract
Trends in phase 3 gynecological clinical trials of targeted therapies: Study oversight and pharmaceutical involvement in the past 12 years.Org: California Pacific Medical Center Research Institute, San Francisco, CA, Stanford University Medical Center, Palo Alto Medical Foundation,
Abstract
Endometrial cancer and obesity trends in the United States in the 21st century.Org: UC Irvine Health, Pingtung Veterans General Hospital, University of California, Irvine Medical Center, California Pacific Medical Center Research Institute, San Francisco, CA, Stanford University Medical Center,
Abstract
The impact of COVID-19 and missed diagnosis of breast cancer.Org: Palo Alto Medical Foundation Research Institute, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, Taiwan, California Pacific Medical Center Research Institute, San Francisco, CA,
Abstract
A retrospective look: Industry partnership and transparency in phase III randomized clinical trials of breast cancer targeted therapies across two decades.Org: California Pacific Medical Center Research Institute, San Francisco, CA, Center for Health Systems Research, Sutter Health, Stanford University Medical Center, Palo Alto Medical Foundation,
Abstract
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).Org: Stanford University Medical Center, University of Miami Health System, Stanford University School of Medicine, Medical Oncology Department, Ramón y Cajal University Hospital, Levine Cancer Institute, Atrium Heath,
Abstract
Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.Org: Brown University/Legorreta Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, University of Kansas Medical Center,
Abstract
Evaluating disparities in receptor status, overall survival, and time to hormone therapy among women with breast cancer.Org: Stanford Cancer Institute, Palo Alto, CA, University of Nevada Las Vegas, Las Vegas, NV, Stanford University School of Medicine,
Abstract
A phase II study of plerixafor combined with whole brain radiation therapy (WBRT) for patients with newly diagnosed glioblastoma.Org: Stanford University School of Medicine, Stanford Cancer Institute Palo Alto, Stanford Cancer Center GI Surgical Oncology, Stanford Cancer Institue, The University of Texas MD Anderson Cancer Center,
Abstract
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Org: Division of Hematology, Mayo Clinic, Rochester, MN, Stanford University Medical Center, Palo Alto, CA, University of Kansas Medical Center, Kansas City, KS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,